

Crystal L Mackall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/633199/publications.pdf>

Version: 2024-02-01

143
papers

21,821
citations

28190
55
h-index

19136
118
g-index

153
all docs

153
docs citations

153
times ranked

20474
citing authors

#	ARTICLE	IF	CITATIONS
1	T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. <i>Lancet, The</i> , 2015, 385, 517-528.	6.3	2,476
2	Current concepts in the diagnosis and management of cytokine release syndrome. <i>Blood</i> , 2014, 124, 188-195.	0.6	2,080
3	4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. <i>Nature Medicine</i> , 2015, 21, 581-590.	15.2	1,304
4	CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. <i>Nature Medicine</i> , 2018, 24, 20-28.	15.2	1,030
5	Convergence of Acquired Mutations and Alternative Splicing of <i>CD19</i> Enables Resistance to CART-19 Immunotherapy. <i>Cancer Discovery</i> , 2015, 5, 1282-1295.	7.7	997
6	Neuroblastoma. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16078.	18.1	907
7	Tumor Antigen Escape from CAR T-cell Therapy. <i>Cancer Discovery</i> , 2018, 8, 1219-1226.	7.7	661
8	Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy. <i>Science Translational Medicine</i> , 2014, 6, 237ra67.	5.8	579
9	The Many Faces of IL-7: From Lymphopoiesis to Peripheral T Cell Maintenance. <i>Journal of Immunology</i> , 2005, 174, 6571-6576.	0.4	509
10	Harnessing the biology of IL-7 for therapeutic application. <i>Nature Reviews Immunology</i> , 2011, 11, 330-342.	10.6	490
11	c-Jun overexpression in CAR T cells induces exhaustion resistance. <i>Nature</i> , 2019, 576, 293-300.	13.7	480
12	Anti-CD22 chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> , 2013, 121, 1165-1174.	0.6	478
13	Clinical lessons learned from the first leg of the CAR T cell journey. <i>Nature Medicine</i> , 2019, 25, 1341-1355.	15.2	400
14	CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 2560-2574.	3.2	369
15	GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. <i>Nature</i> , 2022, 603, 934-941.	13.7	339
16	CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. <i>Nature Communications</i> , 2016, 7, 12320.	5.8	325
17	Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. <i>Nature Medicine</i> , 2018, 24, 572-579.	15.2	321
18	Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma. <i>Cancer Discovery</i> , 2018, 8, 944-957.	7.7	313

#	ARTICLE	IF	CITATIONS
19	Constraints on CD4 Recovery Postchemotherapy in Adults: Thymic Insufficiency and Apoptotic Decline of Expanded Peripheral CD4 Cells. <i>Blood</i> , 1997, 90, 3789-3798.	0.6	300
20	Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. <i>Science</i> , 2021, 372, .	6.0	297
21	Tuning the Antigen Density Requirement for CAR T-cell Activity. <i>Cancer Discovery</i> , 2020, 10, 702-723.	7.7	296
22	CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1938-1950.	0.8	273
23	CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. <i>Nature Medicine</i> , 2021, 27, 1419-1431.	15.2	273
24	Programming CAR-T cells to kill cancer. <i>Nature Biomedical Engineering</i> , 2018, 2, 377-391.	11.6	267
25	Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase. <i>Molecular Therapy</i> , 2017, 25, 2189-2201.	3.7	264
26	Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas. <i>Cancer Immunology Research</i> , 2016, 4, 869-880.	1.6	258
27	Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 1364-1370.	3.2	251
28	The Emerging Landscape of Immune Cell Therapies. <i>Cell</i> , 2020, 181, 46-62.	13.5	247
29	Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. <i>Immunological Reviews</i> , 1997, 157, 61-72.	2.8	218
30	Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADV1412): a multicentre, open-label, single-arm, phase 1 trial. <i>Lancet Oncology</i> , The, 2020, 21, 541-550.	5.1	202
31	Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. <i>Blood</i> , 2015, 125, 784-792.	0.6	200
32	T-Cell Immunodeficiency Following Cytotoxic Antineoplastic Therapy: A Review. <i>Stem Cells</i> , 2000, 18, 10-18.	1.4	182
33	Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL. <i>Journal of Clinical Oncology</i> , 2021, 39, 1650-1659.	0.8	173
34	Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. <i>Nature Medicine</i> , 2020, 26, 712-719.	15.2	172
35	Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. <i>Cancer Cell</i> , 2017, 32, 295-309.e12.	7.7	148
36	CAR T cell therapy: inroads to response and resistance. <i>Nature Reviews Immunology</i> , 2019, 19, 73-74.	10.6	148

#	ARTICLE	IF	CITATIONS
37	Pharmacologic control of CAR-T cell function using dasatinib. <i>Blood Advances</i> , 2019, 3, 711-717.	2.5	143
38	A Pilot Study of Consolidative Immunotherapy in Patients with High-Risk Pediatric Sarcomas. <i>Clinical Cancer Research</i> , 2008, 14, 4850-4858.	3.2	142
39	Assessment of programmed death-1 expression and tumor-associated immune cells in pediatric cancer tissues. <i>Cancer</i> , 2017, 123, 3807-3815.	2.0	135
40	Novel NanoLuc substrates enable bright two-population bioluminescence imaging in animals. <i>Nature Methods</i> , 2020, 17, 852-860.	9.0	123
41	Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers. <i>Cancer Cell</i> , 2017, 31, 476-485.	7.7	116
42	Clinical Trial Designs for the Early Clinical Development of Therapeutic Cancer Vaccines. <i>Journal of Clinical Oncology</i> , 2001, 19, 1848-1854.	0.8	113
43	Autologous lymphapheresis for the production of chimeric antigen receptor T cells. <i>Transfusion</i> , 2017, 57, 1133-1141.	0.8	110
44	Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas. <i>Clinical Cancer Research</i> , 2016, 22, 3182-3191.	3.2	109
45	Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication. <i>Nature Medicine</i> , 2022, 28, 333-344.	15.2	105
46	Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells. <i>Cytotherapy</i> , 2016, 18, 893-901.	0.3	104
47	Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. , 2019, 7, 276.		101
48	Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 218-218.	0.6	98
49	Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 143-155.	2.5	92
50	Focus on sarcomas. <i>Cancer Cell</i> , 2002, 2, 175-178.	7.7	89
51	Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. <i>Cell</i> , 2022, 185, 1745-1763.e22.	13.5	88
52	Immune-based therapies for childhood cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 693-703.	12.5	84
53	Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. <i>Immunity</i> , 2021, 54, 586-602.e8.	6.6	80
54	Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors. <i>Science Advances</i> , 2022, 8, eabn8264.	4.7	80

#	ARTICLE	IF	CITATIONS
55	Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. <i>Journal of Clinical Oncology</i> , 2022, 40, 945-955.	0.8	79
56	Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3034-3043.	0.8	76
57	Driving CAR T cell translation forward. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	61
58	GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. <i>Cancer Cell</i> , 2022, 40, 53-69.e9.	7.7	60
59	Immune receptor inhibition through enforced phosphatase recruitment. <i>Nature</i> , 2020, 586, 779-784.	13.7	59
60	Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts. <i>Blood</i> , 2009, 114, 3831-3840.	0.6	58
61	Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies. , 2020, 8, e001159.		55
62	Fludarabine and neurotoxicity in engineered T-cell therapy. <i>Gene Therapy</i> , 2018, 25, 176-191.	2.3	54
63	Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET. <i>Clinical Cancer Research</i> , 2021, 27, 1058-1068.	3.2	53
64	CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR ⁺ refractory large B-cell lymphoma. <i>Blood</i> , 2021, 137, 2321-2325.	0.6	51
65	Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. <i>Blood Advances</i> , 2022, 6, 1961-1968.	2.5	47
66	Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model. <i>Oncot Immunology</i> , 2020, 9, 1757360.	2.1	46
67	Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies. <i>Blood</i> , 2018, 132, 490-490.	0.6	43
68	Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2149-2154.	2.0	42
69	Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2019, 134, 744-744.	0.6	42
70	Phase 1 Study of CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR) Therapy in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2018, 132, 898-898.	0.6	40
71	Frontiers in cancer immunotherapy ² a symposium report. <i>Annals of the New York Academy of Sciences</i> , 2021, 1489, 30-47.	1.8	39
72	Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop. <i>Cancer Genetics</i> , 2016, 209, 182-194.	0.2	38

#	ARTICLE	IF	CITATIONS
73	NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity. <i>Blood Cancer Discovery</i> , 2021, 2, 648-665.	2.6	37
74	T-Cell Immunodeficiency Following Cytotoxic Antineoplastic Therapy: A Review. <i>Oncologist</i> , 1999, 4, 370-378.	1.9	37
75	Dynamic chromatin regulatory landscape of human CAR T cell exhaustion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	36
76	Safety and Response of Incorporating CD19 Chimeric Antigen Receptor T Cell Therapy in Typical Salvage Regimens for Children and Young Adults with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 684-684.	0.6	35
77	Minimal Residual Disease Negative Complete Remissions Following Anti-CD22 Chimeric Antigen Receptor (CAR) in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2016, 128, 650-650.	0.6	34
78	Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report. <i>Blood Advances</i> , 2022, 6, 600-610.	2.5	32
79	CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering. <i>Blood</i> , 2020, 136, 53-54.	0.6	28
80	ADVL1412: Initial results of a phase I/II study of nivolumab and ipilimumab in pediatric patients with relapsed/refractory solid tumorsâ€”A COG study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10526-10526.	0.8	26
81	PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors. <i>Cancer Research</i> , 2020, 80, 4731-4740.	0.4	24
82	Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days. <i>Blood Advances</i> , 2021, 5, 5312-5322.	2.5	24
83	Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer. <i>European Journal of Cancer</i> , 2022, 160, 112-133.	1.3	24
84	Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , 2016, 22, 3643-3650.	3.2	23
85	Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming. <i>Clinical Cancer Research</i> , 2021, 27, 6054-6064.	3.2	23
86	Tocilizumab-Refractory Cytokine Release Syndrome (CRS) Triggered By Chimeric Antigen Receptor (CAR)-Transduced T Cells May Have Distinct Cytokine Profiles Compared to Typical CRS. <i>Blood</i> , 2016, 128, 3358-3358.	0.6	22
87	Neurotoxicity Associated with a High-Affinity GD2 CARâ€”Letter. <i>Cancer Immunology Research</i> , 2018, 6, 494-495.	1.6	21
88	Clinical Activity and Persistence of Anti-CD22 Chimeric Antigen Receptor in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2015, 126, 1324-1324.	0.6	21
89	Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation. , 2022, 10, e004483.		21
90	Open label, non-randomized, multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1^{c259}t in HLA-A2⁺ patients with synovial sarcoma (NCT01343043).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3000-3000.	0.8	20

#	ARTICLE	IF	CITATIONS
91	A Fructo-Oligosaccharide Prebiotic Is Well Tolerated in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Dose-Escalation Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 932.e1-932.e11.	0.6	18
92	Bioinformatic Description of Immunotherapy Targets for Pediatric T-Cell Leukemia and the Impact of Normal Gene Sets Used for Comparison. <i>Frontiers in Oncology</i> , 2014, 4, 134.	1.3	13
93	Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucl Therapy. <i>Blood</i> , 2019, 134, 550-550.	0.6	13
94	Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucl, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 884-884.	0.6	13
95	A phase 1, open-label, dose escalation study of enoblituzumab (MGA271) in pediatric patients with B7-H3-expressing relapsed or refractory solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS2596-TPS2596.	0.8	13
96	Neurotoxicity following CD19/CD28 ζ CAR T-cells in children and young adults with B-cell malignancies. <i>Neuro-Oncology</i> , 2022, 24, 1584-1597.	0.6	12
97	Engineering a designer immunotherapy. <i>Science</i> , 2018, 359, 990-991.	6.0	11
98	Disease detection methodologies in relapsed B α cell acute lymphoblastic leukemia: Opportunities for improvement. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28149.	0.8	11
99	Target Antigen Downregulation and Other Mechanisms of Failure after Axicabtagene Ciloleucl (CAR19) Therapy. <i>Blood</i> , 2018, 132, 4656-4656.	0.6	11
100	Low CD19 Antigen Density Diminishes Efficacy of CD19 CAR T Cells and Can be Overcome By Rational Redesign of CAR Signaling Domains. <i>Blood</i> , 2018, 132, 963-963.	0.6	10
101	A Prospective Evaluation of Neurocognitive Function and Neurologic Symptoms in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Undergoing Anti-CD22 Chimeric Antigen Receptor Therapy. <i>Blood</i> , 2016, 128, 1625-1625.	0.6	10
102	Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucl That Is out of Specification for Commercial Release. <i>Blood</i> , 2020, 136, 42-44.	0.6	8
103	Factors Impacting Overall and Event-Free Survival following Post-Chimeric Antigen Receptor T Cell Consolidative Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 31.e1-31.e9.	0.6	8
104	Elevated Serum Interleukin-7 Levels Precede the Development of Acute Graft-Versus-Host Disease.. <i>Blood</i> , 2007, 110, 1064-1064.	0.6	8
105	Immune-Based Approaches for the Treatment of Pediatric Malignancies. <i>Annual Review of Cancer Biology</i> , 2020, 4, 353-370.	2.3	7
106	Abstract CT031: GD2 CAR T cells mediate clinical activity and manageable toxicity in children and young adults with DIPG and H3K27M-mutated diffuse midline gliomas. , 2021, , .		7
107	EPCT-14. GD2 CAR T-CELLS MEDIATE CLINICAL ACTIVITY AND MANAGEABLE TOXICITY IN CHILDREN AND YOUNG ADULTS WITH H3K27M-MUTATED DIPG AND SPINAL CORD DMG. <i>Neuro-Oncology</i> , 2021, 23, i49-i50.	0.6	6
108	Infectious Complications Associated with CAR T-Cell Therapy. <i>Blood</i> , 2019, 134, 4449-4449.	0.6	6

#	ARTICLE	IF	CITATIONS
109	Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia. <i>Blood</i> , 2021, 138, 2138-2142.	0.6	5
110	Monitoring ctDNA in r/r DLBCL patients following the CAR T-cell therapy axicabtagene ciloleucel: Day 28 landmark analysis. <i>Journal of Clinical Oncology</i> , 2019, 37, 7552-7552.	0.8	5
111	Gene editing to enhance the efficacy of cancer cell therapies. <i>Molecular Therapy</i> , 2021, 29, 3153-3162.	3.7	5
112	Allogeneic Chimeric Antigen Receptor-Invariant Natural Killer T Cells Exert Both Direct and Indirect Antitumor Effects through Host CD8 T Cell Cross-Priming. <i>Blood</i> , 2019, 134, 867-867.	0.6	5
113	Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 576-576.	0.6	4
114	CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 741-741.	0.6	4
115	Bleeding and Thrombosis Are Associated with Endothelial Dysfunction in CAR-T Cell Therapy and Are Increased in Patients Experiencing Neurologic Toxicity. <i>Blood</i> , 2020, 136, 32-33.	0.6	4
116	Targeting pediatric malignancies for T cell-mediated immune responses. <i>Current Oncology Reports</i> , 2000, 2, 539-546.	1.8	3
117	Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA). <i>Blood</i> , 2020, 136, 49-50.	0.6	3
118	Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report. , 2020, 8, e001073.		2
119	Emerging Immunotherapies for Cancer and Their Potential for Application in Pediatric Oncology. <i>Critical Reviews in Oncogenesis</i> , 2015, 20, 315-327.	0.2	2
120	Synthetic Chimeric Antigen Receptors (CARs) Rapidly Induce Exhaustion and Augmented Glycolytic Metabolism In Human T Cells and Implicate Persistent CD28 Signaling As a Driver Of Exhaustion In Human T Cells. <i>Blood</i> , 2013, 122, 192-192.	0.6	2
121	Abstract 61: Transient "rest" reinvigorates exhausted CAR T cells via epigenetic remodeling. , 2021, , .		1
122	Myeloid Cells in Peripheral Blood Mononuclear Cell (PMBC) Concentrates Inhibit the Expansion of Chimeric Antigen Receptor (CAR) T Cells. <i>Blood</i> , 2015, 126, 383-383.	0.6	1
123	Phase II study of epacadostat with pembrolizumab in metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma requiring paired biopsies. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS191-TPS191.	0.8	1
124	Abstract CT142: GD2.Ox40.CD28.z CAR T cell trial in neuroblastoma and osteosarcoma. <i>Cancer Research</i> , 2022, 82, CT142-CT142.	0.4	1
125	Effectiveness of chemotherapy in non-rhabdomyosarcoma soft tissue sarcomas-response. <i>Pediatric Blood and Cancer</i> , 2005, 45, 228-228.	0.8	0
126	Reply to "IL-7 from dendritic cells essential for the homeostasis of CD4+ T cells" Nature Immunology, 2010, 11, 548-548.	7.0	0

#	ARTICLE	IF	CITATIONS
127	Chimeric Antigen Receptors for Cancer: Progress and Challenges. <i>Current Stem Cell Reports</i> , 2015, 1, 187-196.	0.7	0
128	Interleukin-7 Over-Expression Regulates T Cell Versus B Cell Lineage Development in the Thymus.. <i>Blood</i> , 2004, 104, 3238-3238.	0.6	0
129	Two Categories of Biologic Effects Induced by IL-7 on Human T Cells.. <i>Blood</i> , 2005, 106, 3303-3303.	0.6	0
130	Evaluation of the CD8+ Tumor Associated vs. Non-Tumor Associated Immune Repertoire in Cancer Patients Following Induction of Lymphopenia and Following CD3/4-1BB Based Expansion.. <i>Blood</i> , 2005, 106, 2390-2390.	0.6	0
131	Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (SCT) with Pre-Transplant Targeted Immune Depletion Results in Rapid Full Donor Engraftment in Pediatric Patients with Malignancy.. <i>Blood</i> , 2005, 106, 3672-3672.	0.6	0
132	Subclinical GVHD Impairs Responses to Dendritic Cell Vaccines Following Allogeneic Transplantation.. <i>Blood</i> , 2005, 106, 571-571.	0.6	0
133	Early Recovery of Thymus-Derived Naïve T Cells in Pediatric Patients (pts) Treated with Non-Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation (NMSCT) for Cancer.. <i>Blood</i> , 2006, 108, 310-310.	0.6	0
134	GVHD Abrogates T Cell Responses to Dendritic Cell Vaccines but Not Vaccine-Induced Proliferation.. <i>Blood</i> , 2007, 110, 1802-1802.	0.6	0
135	Loss of IFN γ Signaling on Donor Bone Marrow Abrogates GVHD but Maintains Immunocompetence.. <i>Blood</i> , 2007, 110, 2180-2180.	0.6	0
136	Interleukin-7 Produced by Antigen Presenting Cells Regulates the Homeostatic Peripheral Expansion of Naive CD4 T Cells.. <i>Blood</i> , 2007, 110, 1333-1333.	0.6	0
137	Depletion of CD25+ T cells and IL-7 administration enhanced anti-tumor effects in mice with B16 melanoma. <i>FASEB Journal</i> , 2008, 22, 1077.15.	0.2	0
138	The T Cell Receptor As An Oncogene: Thymic Expression Of Self-Reactive T Cell Receptors Targeting Survivin Induces T-Cell Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 167-167.	0.6	0
139	Latest in Clinical Application of CAR Cell Therapy for B-cell Malignancy and Transplantation. <i>Blood</i> , 2015, 126, SCI-24-SCI-24.	0.6	0
140	Identification of Dual Positive CD19+/CD3+ T Cells in an Apheresis Product Undergoing Chimeric Antigen Receptor (CAR) Transduction. <i>Blood</i> , 2019, 134, 4471-4471.	0.6	0
141	Shared Expression of CD93 and Other Antigens By AML and Endothelial Cells Highlights a Need for Rational Combinatorial Targeting. <i>Blood</i> , 2020, 136, 22-22.	0.6	0
142	YIA22-001: Development of hKIT Chimeric Antigen Receptor T-Cells as Dual Hematopoietic Stem Cell Transplantation Conditioning and Immunotherapeutic Agents for Cure of Pediatric Acute Myeloid Leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, YIA22-001.	2.3	0
143	Outcomes of Hispanic and non-Hispanic white pediatric and young adult patients with B-cell acute lymphoblastic leukemia after commercial tisagenlecleucel.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10016-10016.	0.8	0